OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals a decline in revenue and gross margin, alongside an increased net loss and operating expenses, which are negative indicators. The Q&A session did not provide additional insights or alleviate concerns. The lack of discussion on operational updates, strategic initiatives, and shareholder returns further contributes to uncertainty. Hence, the sentiment is negative, anticipating a stock price decline of -2% to -8% over the next two weeks.
Key Financial Performance
Revenue $211.5 million, a decrease of 5% year-over-year, primarily due to lower sales in the diagnostics segment.
Gross Margin 47.2%, down from 49.8% year-over-year, impacted by increased costs in the diagnostics business.
Net Loss $28.3 million, compared to $24.7 million in the prior year, driven by higher operating expenses.
Operating Expenses $120.4 million, an increase of 3% year-over-year, attributed to investments in R&D and marketing.
Cash and Cash Equivalents $85.7 million, a decrease from $92.1 million year-over-year, due to higher capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Management highlighted that forward-looking statements are subject to risks and uncertainties that could materially affect the company's results. These risks are detailed in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2025.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Officer
Adam Logal
Advisors LLC
CEO President
CFO Chief
Chairman Adam
Chen HC
Cheng JPMorgan
Chief Accounting
Co Research
DeGeeter Ladenburg
Director Alliance
Division Kevin
Division Lut
Division Yale
Division Yi
EDT Edward
Frost Chairman
Inc Research
Kevin DeGeeter
LLC Maurice
LLC Research
Ladenburg Thalmann
Laidlaw PM
Lut Ming
Maurice Raycroft
Ming Cheng
Officer Treasurer
PM EDT
Phillip Frost
Research Division
Tenthoff Piper
Thalmann Co
Treasurer Gary
OPK Transcript
OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
Unknown4-28
The earnings call summary reveals a decline in revenue and gross margin, alongside an increased net loss and operating expenses, which are negative indicators. The Q&A session did not provide additional insights or alleviate concerns. The lack of discussion on operational updates, strategic initiatives, and shareholder returns further contributes to uncertainty. Hence, the sentiment is negative, anticipating a stock price decline of -2% to -8% over the next two weeks.
OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call highlights a decline in revenue and increased losses, despite some growth in specific segments like the 4Kscore test. The Q&A section reveals uncertainties around key projects and a lack of detailed timelines for critical milestones. Although there's a commitment to shareholder returns through repurchases, the overall financial health and guidance adjustments suggest a negative sentiment, potentially leading to a stock price decrease.
OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript
Unknown10-29
The earnings call presents a mixed picture. Financial performance shows some decline in net income, but there's optimism in product development with potential growth in the 4Kscore product and new collaborations. Market strategy is unclear, with slow market conversion for Pfizer products. Expenses are high, impacting financial health. The shareholder return plan is not explicitly positive or negative. The Q&A reveals uncertainties in efficacy and market conversion. Overall, the rating is neutral due to balanced positives and negatives, with no strong catalysts for significant stock price movement.
OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript
Positive7-31
The earnings call shows positive developments: a strategic sale to Labcorp, promising product development, and cost reduction initiatives. The Q&A highlights growth in NGENLA prescriptions, 4Kscore test sales, and potential for oxyntomodulin in obesity/MASH treatment. The share repurchase program and cash flow positive guidance further boost sentiment. Despite some management ambiguity, the overall outlook is positive, with optimistic guidance and strategic initiatives likely to drive a stock price increase in the short term.
OPK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
